ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Unveiling the landscape of pathomics in personalized immunotherapy for lung cancer: a bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Pooled it
- Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.Nature communications · 2021Trial
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.Experimental dermatology · 2026Review
- Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.Nature reviews. Clinical oncology · 2026Review
- Article
- Label-Efficient Deep Color Deconvolution of Brightfield Multiplex IHC Images.IEEE transactions on medical imaging · 2026Article
- Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning models.NPJ precision oncology · 2026Article
- Recent advances in tumor-activated prodrug nanoparticles for cancer immunotherapy.Frontiers in immunology · 2026Review
- Biological mechanism and immune response of MHC-II expression in tumor cells.Cancer biology & medicine · 2025Review
- StereoMM: a graph fusion model for integrating spatial transcriptomic data and pathological images.Briefings in bioinformatics · 2025Article
- An algorithmic perspective on deciphering cell-cell interactions with spatial omics data.Briefings in bioinformatics · 2025Review
- Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy.Archives of dermatological research · 2025Review
- The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.Cancer research communications · 2025Article
- Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors.Molecular cancer · 2025Review
- Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.Journal for immunotherapy of cancer · 2025Review
- Article
- A flexible systems analysis pipeline for elucidating spatial relationships in the tumor microenvironment linked with cellular phenotypes and patient-level features.Frontiers in immunology · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Douglas B Johnson *Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vanderbilt.edu.
Jennifer Bordeaux *Navigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Ju Young KimNavigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Christine VaupelNavigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
David L RimmYale University, New Haven, Connecticut.
Thai H HoMayo Clinic, Jacksonville, Florida and Phoenix, Arizona.ORCID 0000-0003-0023-2939
Richard W JosephMayo Clinic, Jacksonville, Florida and Phoenix, Arizona.ORCID 0000-0001-6102-4661
Adil I DaudUniversity of California, San Francisco, California.ORCID 0000-0002-6617-8421
Robert M ConryUniversity of Alabama, Birmingham, Alabama.
Elizabeth M GaughanUniversity of Virginia, Charlottesville, Virginia.
Leonel F Hernandez-AyaWashington University in St. Louis, St. Louis, Missouri.
Anastasios DimouMedical University of South Carolina, Charleston, South Carolina.
Pauline FunchainCleveland Clinic, Cleveland, Ohio.
James SmithyYale University, New Haven, Connecticut.ORCID 0000-0003-3126-1193
John S WitteUniversity of California, San Francisco, California.
Svetlana B McKeeUniversity of Alabama, Birmingham, Alabama.
Jennifer KoCleveland Clinic, Cleveland, Ohio.ORCID 0000-0003-0629-775X
John M WrangleMedical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-4263-5974
Bashar DabbasNavigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Shabnam TangriNavigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Jelveh LamehNavigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Jeffrey HallGenoptix, Inc., Carlsbad, California.
Joseph MarkowitzMoffitt Cancer Center, Tampa, Florida.
Justin M BalkoVanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-4263-5974
Naveen DakappagariNavigate BioPharma Services, Inc., a Novartis Subsidiary, Carlsbad, California.
Funding
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3MLong-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3MPredicting and profiling long-term survival after immune checkpoint inhibitionK23CA204726 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B · 2016 to 2020
$756kNCI NIH HHS K12 CA090625NCI NIH HHS K23 CA204726NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL155990
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorBiopsyCell Line, TumorFemaleHLA-DR AntigensHumansImmunohistochemistryIndoleamine-Pyrrole 2,3,-DioxygenaseMaleMelanomaMiddle AgedModels, BiologicalAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanHLA-DR AntigensIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.